Rhenium-188 P 2045

Drug Profile

Rhenium-188 P 2045

Alternative Names: BAY-865284; NeoTide; P2045; Re-188 P 2045; Rh-188 P2045; Rhenium-188 P2045; Tozaride

Latest Information Update: 08 Apr 2016

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Andarix Pharmaceuticals
  • Class Antineoplastics; Heavy metals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Small cell lung cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Small cell lung cancer
  • Preclinical Pancreatic cancer

Most Recent Events

  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 15 Mar 2010 P2045 is still in active development for Cancer
  • 11 Aug 2009 Bryan Oncor acquires P2045 from Antisoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top